Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Giembycz

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
British Journal of Pharmacology|May 27, 2009
An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilatorsMark A Giembycz
Current Opinion in Pharmacology|May 24, 2005
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitorsMark A Giembycz
Proceedings of the American Thoracic Society|November 4, 2005
Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary diseaseMark A Giembycz
British Journal of Clinical Pharmacology|July 18, 2006
An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseMark A Giembycz
British Journal of Pharmacology|September 21, 2016
Understanding how long-acting β<sub>2</sub> -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an updateRobert Newton, Mark A Giembycz
Handbook of Experimental Pharmacology|June 23, 2011
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapiesMark A Giembycz, Robert Newton
F1000Prime Reports|March 10, 2015
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesMark A Giembycz, Robert Newton
Clinics in Chest Medicine|February 11, 2014
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotypeMark A Giembycz, Robert Newton
Current Opinion in Pharmacology|May 10, 2014
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary diseaseMark A Giembycz, Donald H Maurice
Drug Design, Development and Therapy|August 7, 2010
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPDMark A Giembycz, Stephen K Field
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
British Journal of Pharmacology|May 27, 2009
An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilatorsMark A Giembycz
Current Opinion in Pharmacology|May 24, 2005
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitorsMark A Giembycz
Proceedings of the American Thoracic Society|November 4, 2005
Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary diseaseMark A Giembycz
British Journal of Clinical Pharmacology|July 18, 2006
An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseMark A Giembycz
British Journal of Pharmacology|September 21, 2016
Understanding how long-acting β<sub>2</sub> -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an updateRobert Newton, Mark A Giembycz
Handbook of Experimental Pharmacology|June 23, 2011
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapiesMark A Giembycz, Robert Newton
F1000Prime Reports|March 10, 2015
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesMark A Giembycz, Robert Newton
Clinics in Chest Medicine|February 11, 2014
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotypeMark A Giembycz, Robert Newton
Current Opinion in Pharmacology|May 10, 2014
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary diseaseMark A Giembycz, Donald H Maurice
Drug Design, Development and Therapy|August 7, 2010
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPDMark A Giembycz, Stephen K Field
Pageof 7